Predictive value of age, estimated glomerular filtration rate and ejection fraction (AGEF) score for all-cause 90-day mortality in patients with cardiogenic shock

年龄、估算肾小球滤过率和射血分数(AGEF)评分对心源性休克患者90天全因死亡率的预测价值

阅读:1

Abstract

AIMS: Age, estimated glomerular filtration rate and ejection fraction (AGEF) score correlates with mortality in patients with ST-elevation myocardial infarction, yet its relationship with cardiogenic shock mortality remains unknown. OBJECTIVES: This research aims to explore the correlation between AGEF and the probability of all-cause 90-day mortality in patients with cardiogenic shock. METHODS: Our study included 168 cardiogenic shock patients from a multicenter, prospective, observational study. The Cox regression model, subgroup analyses, Kaplan-Meier survival curves, and restricted cubic spline analysis were applied to assess the relationship between AGEF and 90-day mortality. Receiver-operating characteristic curve analysis was performed to evaluate the predictive accuracy of AGEF for 90-day mortality. RESULTS: High AGEF scores correlated with significantly higher mortality (56.1 vs. 19.7%, P < 0.05). AGEF was significantly associated with 90-day mortality [hazard ratio: 1.33, per 1-point increase, 95% confidence interval (95% CI) 1.03-1.70, P < 0.001; hazard ratio: 1.65, per 1 standard deviation increase, 95% CI 1.27-2.14, P < 0.001]. The high AGEF group had a two-fold higher risk of 90-day mortality (hazard ratio: 3.08, 95% CI 1.48-6.41, P < 0.001). Kaplan-Meier curve analysis revealed a higher probability of 90-day death in the group with higher AGEF scores. The restricted cubic spline analysis also suggested a linear relationship between AGEF and 90-day mortality. The area under the receiver-operating characteristic curve for the AGEF was 0.71 (95% CI 0.633-0.787), indicating moderate discrimination ability. CONCLUSION: AGEF is significantly associated with all-cause 90-day mortality in patients experiencing cardiogenic shock, indicating its potential as a prognostic indicator in this patient population.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。